Skip to main content
. 2023 Aug 29;14:158. doi: 10.1007/s12672-023-00774-4

Fig. 2.

Fig. 2

The overall survival (a) and the progression free survival (b) for patients administered PTX, PTX + Cmab, and S1. No significant differences in OS and PFS were observed between the chemotherapy groups